Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.

26 Oct 2012

Glioblastoma multiforme can originate from cortical neurons

Scientists have long believed that glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. In a paper published October 18 in Science Express, however, researchers at the Salk Institute for Biological Studies have found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.

23 Oct 2012

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

The good news widely reported this morning of positive results from a clinical drug trial at Boston Children's Hospital for the previously "untreatable" rapid aging disorder in children known as progeria has its scientific roots in basic biology discoveries made in recent years.

26 Sep 2012

Flow cytometry isolates stem cells from brain tumors

A new video protocol in Journal of Visualized Experiments (JoVE) details an assay to identify brain tumor initiating stem cells from primary brain tumors. Through flow cytometry, scientists separate stem cells from the rest of the tumor, allowing quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Lonafarnib proves effective for children with progeria

Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.

25 Sep 2012

NeuroTouch system provides 3-d graphics and tactile feedback during brain cancer surgery

A new virtual reality simulator-including sophisticated 3-D graphics and tactile feedback-provides neurosurgery trainees with valuable opportunities to practice essential skills and techniques for brain cancer surgery, according to a paper in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

24 Sep 2012

A mysterious form of cell death uncovers prime suspect for new cancer drug development

A mysterious form of cell death, coded in proteins and enzymes, led to a discovery by UNC researchers uncovering a prime suspect for new cancer drug development.

15 Sep 2012

Bioengineers design nanoparticles that can safely and predictably infiltrate deep into the brain

The brain is a notoriously difficult organ to treat, but Johns Hopkins researchers report they are one step closer to having a drug-delivery system flexible enough to overcome some key challenges posed by brain cancer and perhaps other maladies affecting that organ.

12 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

New strategy will have positive impact on people with brain disorders

New research offers a possible strategy for treating central nervous system diseases, such as brain and spinal cord injury, brain cancer, epilepsy, and neurological complications of HIV. The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.

10 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively.

16 Aug 2012

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Despite years of research, glioblastoma, the most common and deadly brain cancer in adults, continues to outsmart treatments targeted to inhibit tumor growth.

15 Aug 2012

Allergies may reduce risk of brain cancer

New research adds to the growing body of evidence suggesting that there's a link between allergies and reduced risk of a serious type of cancer that starts in the brain. This study suggests the reduced risk is stronger among women than men, although men with certain allergy profiles also have a lower tumor risk.

3 Aug 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Brain Cancer News and Research

Further Reading

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Glioblastoma multiforme can originate from cortical neurons

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

Flow cytometry isolates stem cells from brain tumors

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Lonafarnib proves effective for children with progeria

NeuroTouch system provides 3-d graphics and tactile feedback during brain cancer surgery

A mysterious form of cell death uncovers prime suspect for new cancer drug development

Bioengineers design nanoparticles that can safely and predictably infiltrate deep into the brain

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

Researchers identify many potential therapeutic targets for squamous cell lung cancers

New strategy will have positive impact on people with brain disorders

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Allergies may reduce risk of brain cancer

Fusion of FGFR and TACC gene leads to glioblastoma

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News